Instrument Inactif

Autres langues Briacell Therapeutics Corp Toronto S.E.

Actions

CA10778Y1043

Recherche biotechnologique et médicale

Autres langues

16/07	BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study
16/07	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT
16/07	BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer
16/07	BriaCell Therapeutics : Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer
16/07	BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
15/07	BriaCell Therapeutics : Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT(TM)
15/07	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
07/07	BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT
07/07	BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
25/06	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT
25/06	BriaCell Therapeutics Inks MOU With Dutch Microneedle Company
25/06	BriaCell Therapeutics : Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)
25/06	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
09/06	BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026
02/06	BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering
02/06	BriaCell Therapeutics Closes $4.7 Million Share Offering
02/06	BriaCell Therapeutics Announces Closing of Offering
01/06	BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting
01/06	BriaCell Presents Positive Clinical Data at ASCO 2026
01/06	BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million
01/06	BriaCell Therapeutics Prices $4.7 Million Share Offering
01/06	Briacell Therapeutics prices 1.45 million common shares at $3.25 per share
01/06	BriaCell Therapeutics Announces Pricing of Offering
26/05	Briacell Therapeutics Corp. Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study of Bria-Imt Plus Immune Checkpoint Inhibitor in Metastatic Breast Cancer
26/05	BriaCell Receives DSMB Nod to Continue With Phase 3 Metastatic Breast Cancer Study